STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPMD
  4. [NT 10-Q] CANNAPHARMARX, INC. SEC Filing

CannaPharmaRX (CPMD) delays June report as gross loss narrows

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
NT 10-Q

Rhea-AI Filing Summary

CannaPharmaRX, Inc. notified regulators that its Form 10-Q for the quarter ended June 30, 2026 will be filed late under Form 12b-25 due to delays in obtaining and compiling required information, which it states could not be resolved without unreasonable effort and expense. The company expects to file the report no later than the fifth calendar day after the original due date. For the three and six months ended June 30, 2026, it reported revenues of $276,218 and $903,680, compared with $231,608 and $566,927 for the same 2025 periods, reflecting higher cannabis sales volumes and increased sales to existing customers. Over the same periods, it recorded gross losses of $138,446 and $547,899, improved from gross losses of $621,210 and $1,123,817 a year earlier, mainly due to higher revenue and lower inventory impairment charges.

Positive

  • Revenues increased to $276,218 and $903,680 for the quarter and six months, up from $231,608 and $566,927, driven by higher cannabis sales volumes.
  • Gross loss narrowed significantly to $138,446 and $547,899 for the quarter and six months, from $621,210 and $1,123,817 in 2025, aided by lower inventory impairment charges.

Negative

  • The company will file its Form 10-Q late and required a Form 12b-25 extension due to delays in obtaining and compiling information.
  • Despite improvement, the company still reported a gross loss of $138,446 for the quarter and $547,899 for the six months ended June 30, 2026.
Quarterly revenue 2026 $276,218 Revenue for the three months ended June 30, 2026
Quarterly revenue 2025 $231,608 Revenue for the three months ended June 30, 2025
Six-month revenue 2026 $903,680 Revenue for the six months ended June 30, 2026
Six-month revenue 2025 $566,927 Revenue for the six months ended June 30, 2025
Quarterly gross loss 2026 $138,446 Gross loss for the three months ended June 30, 2026
Quarterly gross loss 2025 $621,210 Gross loss for the three months ended June 30, 2025
Six-month gross loss 2026 $547,899 Gross loss for the six months ended June 30, 2026
Six-month gross loss 2025 $1,123,817 Gross loss for the six months ended June 30, 2025
Form 12b-25 regulatory
"FORM 12b-25 | SEC FILE NUMBER"
Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.
Rule 12b-25 regulatory
"In accordance with Rule 12b-25 of the Securities Exchange Act of 1934"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
gross loss financial
"the Company reported a gross loss of $138,446 and $547,899"
Gross loss is the total amount of money a business or investment lost before subtracting recoveries, insurance reimbursements, refunds, taxes, or other adjustments. Think of it as the sticker price of a loss—what was lost on paper before any offsets or fixes are applied—which helps investors see the raw scale of a problem and compare underlying performance across periods or peers.
inventory impairment charges financial
"primarily due to increased revenue and lower inventory impairment charges"

FAQ

Why is CannaPharmaRX (CPMD) filing its June 30, 2026 Form 10-Q late?
CannaPharmaRX is filing late because it faced a delay in obtaining and compiling information needed for the Form 10-Q, which it states could not be resolved without unreasonable effort or expense. It expects to file within five calendar days of the original due date.

When does CannaPharmaRX (CPMD) expect to file the delayed June 30, 2026 Form 10-Q?
CannaPharmaRX states it will file the Form 10-Q no later than the fifth calendar day after the prescribed due date, relying on the extension provided under Rule 12b-25 for quarterly reports.

What revenues did CannaPharmaRX (CPMD) report for the quarter ended June 30, 2026?
For the quarter ended June 30, 2026, CannaPharmaRX reported revenue of $276,218, compared with $231,608 in the same quarter of 2025. The company attributes the increase primarily to higher cannabis sales volumes and increased sales to existing customers.

How did CannaPharmaRX (CPMD) perform over the six months ended June 30, 2026?
Over the six months ended June 30, 2026, CannaPharmaRX reported revenue of $903,680, up from $566,927 a year earlier. The company also reduced its gross loss to $547,899 from $1,123,817 in the prior-year period.

What gross losses did CannaPharmaRX (CPMD) report for the recent quarter and year-to-date?
For the quarter ended June 30, 2026, CannaPharmaRX reported a gross loss of $138,446, versus $621,210 in 2025. For the six months, gross loss was $547,899 compared with $1,123,817, helped by higher revenue and lower inventory impairment charges.

What drove the changes in CannaPharmaRX (CPMD) results versus the prior year?
The company states that higher cannabis sales volumes, including increased sales to existing customers, boosted revenue. It adds that lower inventory impairment charges contributed to the reduction in gross loss compared with the 2025 periods.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 Expires: September 30, 2028
Estimated average burden
  Washington, D.C. 20549 hours per response.......2.50
     
  FORM 12b-25 SEC FILE NUMBER
  000-27055
     
    CUSIP NUMBER
  NOTIFICATION OF LATE FILING 13765D109

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K    
  ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
                 
  For Period Ended: June 30, 2026
         
  ☐ Transition Report on Form 10-K
  ☐ Transition Report on Form 20-F
  ☐ Transition Report on Form 11-K
  ☐ Transition Report on Form 10-Q
     
  For the Transition Period Ended: __________________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 
PART I - REGISTRANT INFORMATION

 

CannaPharmaRX, Inc.  
Full Name of Registrant  

 

 

  
Former Name if Applicable
 
4439 Township Rd 304  
Address of Principal Executive Office (Street and Number)
 
Mountain View County, Alberta, Canada T0M 0R0  
City, State and Zip Code

 

 
 

 

 

 

   

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

☒ (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
   
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

(Attach extra Sheets if Needed)

 

The Registrant could not complete the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 due to a delay in obtaining and compiling information required to be included in its Form 10-Q, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Registrant will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Constantine Nkafu   (403)   637-0420
(Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
   
(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒ No ☐

   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

During the three and six months ended June 30, 2026, the Company reported revenues of $276,218 and $903,680, respectively (2025 - $231,608 and $566,927, respectively). The increase from the prior-year comparable periods was primarily driven by higher cannabis sales volumes, including increased sales to existing customers.

 

During the three and six months ended June 30, 2026, the Company reported a gross loss of $138,446 and $547,899, respectively (2025 - $621,210 and $1,123,817, respectively). The decrease from the prior-year comparable periods was primarily due to increased revenue and lower inventory impairment charges.

 

 

 

 

 2 

 

 

CannaPharmaRX, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 17, 2026 By: /s/ Oliver Foeste  
    Oliver Foeste  
    Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

Source: View Original Filing on SEC EDGAR